Pathologically decreased csf levels of synaptic marker nptx2 in dlb are correlated with levels of alpha-synuclein and vgf

Walter A. Boiten, Inger van Steenoven, Meifang Xiao, Paul F. Worley, Afina W. Lemstra, Charlotte E. Teunissen

Research output: Contribution to journalArticleAcademicpeer-review

14 Citations (Scopus)


Background: Dementia with Lewy bodies (DLB) is a neurodegenerative disease where synaptic loss and reduced synaptic integrity are important neuropathological substrates. Neuronal Pentraxin 2(NPTX2) is a synaptic protein that drives the GABAergic inhibitory circuit. Our aim was to examine if NPTX2 cerebral spinal fluid (CSF) levels in DLB patients were altered and how these levels related to other synaptic protein levels and to cognitive function and decline. Methods: NPTX2, VGF, and α-synuclein levels were determined in CSF of cognitive healthy (n = 27), DLB (n = 48), and AD (n = 20) subjects. Multiple cognitive domains were tested, and data were compared using linear models. Results: Decreased NPTX2 levels were observed in DLB (median = 474) and AD (median = 453) compared to cognitive healthy subjects (median = 773). Strong correlations between NPTX2, VGF, and α-synuclein were observed dependent on diagnosis. Combined, these markers had a high differentiating power between DLB and cognitive healthy subjects (AUC = 0.944). Clinically, NPTX2 levels related to global cognitive function and cognitive decline in the visual spatial domain. Conclusion: NPTX2 CSF levels were reduced in DLB and closely correlated to decreased VGF and α-synuclein CSF levels. CSF NPTX2 levels in DLB related to decreased functioning in the visual spatial domain.

Original languageEnglish
Article number38
Pages (from-to)1-13
Number of pages13
Issue number1
Publication statusPublished - 29 Dec 2020


  • Alzheimer’s disease
  • Biomarkers
  • Cerebral spinal fluid
  • Cognitive function
  • Dementia with Lewy bodies
  • Neuronal pentraxin 2
  • VGF (non-acronym)
  • Visual spatial domain
  • α-synuclein

Cite this